Clinical Trials Logo

Glioblastoma clinical trials

View clinical trials related to Glioblastoma.

Filter by:

NCT ID: NCT03861598 Terminated - Glioblastoma Clinical Trials

Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells

Start date: July 19, 2019
Phase: Early Phase 1
Study type: Interventional

Subjects will receive standard chemotherapy and Tumor Treated Fields (TTFields) and will also receive Carvedilol for 4 cycles of treatment. Carvedilol will start at 6.25 mg orally twice a day and be increased to 12.5 mg orally twice daily after 1 to 2 weeks if tolerated. Peripheral glioma circulating tumor cells (CTC) and brain MRI with and without contrast will be obtained at baseline, 2 cycles, and 4 cycles to determine the efficacy and direction of change of the CTC using a new assay tool. Preliminary assessment of the tolerability of Carvedilol with standard chemotherapy will also be evaluated.

NCT ID: NCT03856099 Terminated - Clinical trials for Recurrent Glioblastoma

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Start date: November 13, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

NCT ID: NCT03714334 Terminated - Glioblastoma Clinical Trials

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

Start date: October 16, 2018
Phase: Phase 1
Study type: Interventional

Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.

NCT ID: NCT03707457 Terminated - Glioblastoma Clinical Trials

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Start date: March 22, 2019
Phase: Phase 1
Study type: Interventional

This research is being done to test if it is safe to give nivolumab with targeted immunotherapy drugs for recurrent glioblastoma (GBM), a type of brain tumor. The study doctors believe that giving immunotherapy drugs that match the biomarkers in a tumor will help the immune system fight the tumor. Tumor tissue collected during surgery will be tested for certain biomarkers to determine which immunotherapy might best target the tumor. The combination immunotherapy arms include: Arm A: Nivolumab + anti-GITR Arm B: Nivolumab + IDO1 inhibitor Arm C: Nivolumab + Ipilimumab

NCT ID: NCT03705351 Terminated - Glioblastoma Clinical Trials

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Start date: December 2, 2019
Phase: Phase 1
Study type: Interventional

The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and schedule.

NCT ID: NCT03593993 Terminated - Glioblastoma Clinical Trials

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Start date: May 19, 2018
Phase:
Study type: Observational

This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.

NCT ID: NCT03573986 Terminated - Clinical trials for Recurrent Glioblastoma

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Start date: April 18, 2018
Phase: Phase 1
Study type: Interventional

Subjects with recurrent glioblastoma who are candidates for bevacizumab treatment according to standard of care will be eligible for this study. Positron emission tomography (PET/CT) imaging will use the investigational radiotracer [18F]FMISO to image the brain and evaluate for hypoxia pre and post therapy.. Subjects will also undergo up to three Brain MRIs.

NCT ID: NCT03430791 Terminated - Clinical trials for Recurrent Glioblastoma

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Start date: December 5, 2018
Phase: Phase 2
Study type: Interventional

Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.

NCT ID: NCT03422094 Terminated - Glioblastoma Clinical Trials

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Start date: October 31, 2018
Phase: Phase 1
Study type: Interventional

This is a single institution, open-label, multi-arm, pilot study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine plus poly-ICLC (NeoVax) combined with immune checkpoint inhibitors in subjects with newly diagnosed, unmethylated glioblastoma.

NCT ID: NCT03419403 Terminated - Clinical trials for Glioblastoma Multiforme

UNITE Study: Understanding New Interventions With GBM ThErapy

Start date: July 30, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).